Information on Guggul - Commiphora Mukul

Guggul Picture

Guggul, a resin from the guggul tree, has been used for centuries in India to treat a range of disorders. This resin has been used as part of India's traditional medicine called Ayurveda.

Guggal an extract of the exudate (gum guggul) of Mukul myrrh tree, contains phytosterols named guggulsterones, organic acids, aromatic acids, diterpenes, lignans, sterols, steroids, esters and fatty acid alcohols. Guggal is preferred to crude gum guggul because it is safer and more effective.

Health Benefits of Guggul

Possible side effects of Guggul

  • Crude guggul extracts can cause side effects such as skin rashes, diarrhea, hiccups, restlessness, apprehension.
  • Guggul is considered an emenogogue (an agent that promotes the menstrual discharge) and a uterine stimulant, and should not be used during pregnancy.
  • Also, caution is recommended with patients currently on prescribed medications for cardiovascular disease.

Guggul Dosage

The dosage of guggulsterones is 25 mg two or three times daily. Most extracts contain 2.5–5% guggulsterones and can be taken daily for 3 to six months.

Note: Guggul capsules, which are increasingly available in health food stores, are made from the purified and standardized gum of the plant and were found to be well tolerated. They usually each contain no less than 25 mg of the bio active components, Z and E-Guggulsterones.

Leave your comments

Health News

Surgeon Removes Eight Pound Liver Tumor

The cancerous tumor in Marcus Muhich's liver weighed 8 pounds and was nearly a foot across. Doctors at three major academic medical centers in the Midwest told Muhich his high-grade tumor was inoperable. Then he was referred to Dr... [ read article ]

NIPPV Linked To Increased Hospital Mortality Rates In Small Group Of Patients

Although increased use of noninvasive positive-pressure ventilation (NIPPV) nationwide has helped decrease mortality rates among patients hospitalized with chronic obstructive pulmonary disease (COPD), a small group of... [ read article ]

FDA Approves Label Update For PREZISTA® To Include 192-Week Data In HIV-1-Infected Adult Patients

Starting Treatment Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study... [ read article ]

Recommended Stuff

Our Latest Blog Entries...